Vir Biotechnology, INC 10-Q quarterly reports

Vir Biotechnology, Inc. announced its Q2 2026 financial results, highlighting a substantial upfront payment from a new collaboration with Astellas, alongside progress in its clinical pipeline.

Vir Biotechnology reports a reduced net loss in Q3 2025, driven by cost savings, despite a significant revenue decline, as its key clinical programs advance ahead of schedule.

Vir Biotechnology, Inc. reported a net loss of $110.96 million for Q2 2025, with significant R&D investments in its hepatitis delta and oncology programs, while maintaining strong liquidity.

Vir Biotechnology announces its Q1 2025 financial results, showcasing progress in its clinical programs for hepatitis delta, hepatitis B, and oncology.

Vir Biotechnology announced its Q3 2024 financial results, a strategic restructuring, and provided updates on its clinical pipeline, including a new licensing agreement with Sanofi.

Vir Biotechnology announced its second quarter 2024 financial results, alongside a strategic restructuring and a new licensing agreement with Sanofi.

Vir Biotechnology reported its first quarter 2024 financial results, highlighted by a significant contract revenue increase and pipeline advancements, while also announcing the departure of its CFO.